Literature DB >> 12720270

MRI of focal nodular hyperplasia (FNH) with gadobenate dimeglumine (Gd-BOPTA) and SPIO (ferumoxides): an intra-individual comparison.

Luigi Grazioli1, Giovanni Morana, Miles A Kirchin, Paolo Caccia, Laura Romanini, Maria P Bondioni, Carlo Procacci, Antonio Chiesa.   

Abstract

PURPOSE: To compare the efficacy of two different MR contrast agents for the detection and diagnosis of focal nodular hyperplasia (FNH).
MATERIALS AND METHODS: Fifty patients with 83 FNH lesions detected on spiral CT were studied in two different MRI sessions with Gd-BOPTA (MultiHance) and ferumoxides (Endorem). MRI with Gd-BOPTA was performed precontrast (T1wGRE and T2wTSE sequences) and during the dynamic and late (1-3 hours) phases after injection (T1wGRE sequences only). MRI with ferumoxides (T1wGRE and T2wTSE sequences) was performed before and at least 30 minutes after injection. Hyper- or isointensity of FNH in the late phase was considered typical for Gd-BOPTA, while isointensity or lesion hypointensity was considered typical for ferumoxides.
RESULTS: With Gd-BOPTA, 83 FNH lesions (100%) appeared hyperintense during the arterial phase of dynamic MRI. All but one lesion was iso- or slightly hyperintense in the portal-venous and equilibrium phases. In the late phase, 81 FNH lesions were hyper- or isointense to the surrounding parenchyma, with two lesions appearing slightly hypointense. With ferumoxides, a significant (P < 0.001) number (21/83, 25.3%) of FNH lesions (mean diameter = 16.8 +/- 6.6 mm) were not visible. Of the visible FNH lesions, 38/62 were slightly hyperintense, and 24/62 were isointense to the surrounding parenchyma on the T2wTSE images. On the T1wGRE images, 42/62 lesions were isointense, 19/62 were slightly hyperintense, and one lesion was slightly hypointense. Seventeen lesions in 12 patients with previous neoplasia were all detected after Gd-BOPTA administration, whereas only nine of these 17 lesions (52.9%) were detected after ferumoxide administration. Two of these nine lesions showed atypical enhancement features.
CONCLUSION: Gd-BOPTA-enhanced MRI is significantly better than ferumoxide-enhanced MRI for the identification and characterization of FNH. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12720270     DOI: 10.1002/jmri.10289

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  12 in total

Review 1.  [Current status of MRI diagnostics with liver-specific contrast agents. Gd-EOB-DTPA and Gd-BOPTA].

Authors:  C Stroszczynski; G Gaffke; M Gnauck; F Streitparth; G Wieners; E Lopez-Häninnen
Journal:  Radiologe       Date:  2004-12       Impact factor: 0.635

2.  Malignant focal liver lesions at contrast-enhanced ultrasonography and magnetic resonance with hepatospecific contrast agent.

Authors:  M D'Onofrio; S Crosara; R De Robertis; S Canestrini; V Cantisani; G Morana; R Pozzi Mucelli
Journal:  Ultrasound       Date:  2013-12-13

3.  Magnetic resonance imaging of the liver: New imaging strategies for evaluating focal liver lesions.

Authors:  Kenneth Coenegrachts
Journal:  World J Radiol       Date:  2009-12-31

Review 4.  Contrast Agents for Hepatocellular Carcinoma Imaging: Value and Progression.

Authors:  Ying Zhang; Kazushi Numata; Yuewu Du; Shin Maeda
Journal:  Front Oncol       Date:  2022-06-02       Impact factor: 5.738

Review 5.  Pediatric liver tumors--a pictorial review.

Authors:  Priyanka Jha; Soni C Chawla; Sidhartha Tavri; Chirag Patel; Charles Gooding; Heike Daldrup-Link
Journal:  Eur Radiol       Date:  2008-08-06       Impact factor: 5.315

Review 6.  Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications.

Authors:  Peter Reimer; Günter Schneider; Wolfgang Schima
Journal:  Eur Radiol       Date:  2004-02-25       Impact factor: 5.315

7.  Solid focal liver lesions: dynamic and late enhancement patterns with the dual phase contrast agent gadobenate dimeglumine.

Authors:  Luigi Grazioli; Maria Pia Bondioni; Niccolò Faccioli; Sebastiana Gambarini; Rita Tinti; Günther Schneider; Miles Kirchin
Journal:  J Gastrointest Cancer       Date:  2010-12

8.  Gadoxetate Acid-Enhanced MR Imaging for HCC: A Review for Clinicians.

Authors:  Jendana Chanyaputhipong; Su-Chong Albert Low; Pierce K H Chow
Journal:  Int J Hepatol       Date:  2011-07-13

Review 9.  Distinguishing benign from malignant liver tumours.

Authors:  Jay P Heiken
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

10.  Characterization of incidental liver lesions: comparison of multidetector CT versus Gd-EOB-DTPA-enhanced MR imaging.

Authors:  Yong Eun Chung; Myeong-Jin Kim; Yeo-Eun Kim; Mi-Suk Park; Jin Young Choi; Ki Whang Kim
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.